insights_auto
Why is LXRX down 4,55%?
Dive Deeperchevron_right
LXRX:NASDAQ
Lexicon Pharmaceuticals Inc
1,68 $
arrow_downward
-4,55%(-0,080) 1D
1,68 $
0,00% (0,00)
bedtimeAfter hours
Closed: 9 հոկ, 16:00:01 GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for LXRX...
Open
1,75 $
High
1,77 $
Low
1,67 $
Mkt. cap
747,53 մլն
Avg. vol.
3,08 մլն
Volume
2,07 մլն
52-wk high
2,68 $
52-wk low
1,10 $
EPS
-0,15 $
Beta
1,36
Shares outstanding
444,96 մլն
No. of employees
81
Open
1,75 $
High
1,77 $
Low
1,67 $
Mkt. cap
747,53 մլն
Avg. vol.
3,08 մլն
Volume
2,07 մլն
52-wk high
2,68 $
52-wk low
1,10 $
EPS
-0,15 $
Beta
1,36
Shares outstanding
444,96 մլն
No. of employees
81
News stories
From web sources and news partners
TradingView
·
29 րոպե առաջ
TRex Bio, Clinical-Stage Immunology Biopharma, Files for Nasdaq Global Select Market IPO
Quiver Quantitative
·
28 րոպե առաջ
Axe Compute Inc. to Ring Nasdaq Opening Bell Amid AI Infrastructure Growth and $3.45 Billion in Signed Contracts
Yahoo Finance
·
5 ժամ առաջ
Moderna Climbs 5% on NASDAQ 100 Entry; Pfizer Inches Higher, BioNTech Ticks Up
GuruFocus
·
1 ժամ առաջ
Nasdaq CEO Flags Tens of Billions in New Wall Street Opportunity
Profile
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company developing treatments for human disease. The company was founded in 1995 in The Woodlands, Texas under the name Lexicon Genetics, Incorporated by co-founders Professor Allan Bradley, FRS and Professor Bradley's postdoctoral fellow Arthur T Sands. The company has used its mouse gene knockout technology and in vivo screening capabilities to study nearly 5,000 genes in its Genome5000 program and has identified over 100 potential therapeutic targets. Lexicon has advanced multiple drug candidates into human clinical trials and has a broad and diverse pipeline of drug targets behind its clinical programs. Lexicon is pursuing drug targets in five therapeutic areas including oncology, gastroenterology, immunology, metabolism, and ophthalmology.
The company's clinical drug candidates include sotagliflozin for the treatment of type 2 diabetes; LX1033 for the treatment of irritable bowel syndrome and other gastrointestinal disorders; telotristat ethyl for the treatment of the symptoms associated with carcinoid syndrome; and LX2931 for the treatment of autoimmune diseases, such as rheumatoid arthritis. Wikipedia
About Lexicon Pharmaceuticals Inc